The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Researchers demonstrated that expressing OSK in vivo in retinal ganglion cells restored older cells to a more youthful state in terms of their methylation patterns, promoted axon regeneration after injury, and reversed age-related vision loss and vision loss due to glaucoma
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
These exciting new findings, led by the Fourier lab, are supportive of work we’ve published with Bruce Ksander’s lab @harvardmed on the acceleration of aging due to injury the reversal of blindness in a 🐁 model of glaucoma & old mice by rejuvenating RGC nerves via OSK https://t.co/UTcPArWnLe
Epigenetic reprogramming works in monkeys to treat an injury to the retina called NAION, basically a stroke in the back of the eye.